← All trials
NCT06286098
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 20, 2024
- Primary completion
- Apr 20, 2025
- Completion date
- Oct 20, 2025
- First posted
- Feb 29, 2024
- Last posted
- Sep 5, 2024
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ain Shams UniversityLead sponsor
- Misr University for Science and TechnologyOfficial
- Ain Shams UniversitySponsor investigator
- EVA pharma, EgyptCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.